{"disease":{"id":"hepatitis-c-virus","name":"hepatitis c virus"},"drugs":{"marketed":[],"pipeline":[{"drug_id":"odalasvir-25-mg","indication_name":"Chronic hepatitis C virus infection (genotypes 1–6)","indication_type":"pipeline","phase":"Phase 2","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Odalasvir 25 mg","company_name":"Janssen Research & Development, LLC","drug_phase":"discontinued","molecular_target":"Hepatitis C virus NS5A protein","drug_class":"Direct-acting antiviral (DAA); NS5A inhibitor","quality_score":null,"revenue":null,"mechanism":"Odalasvir inhibits hepatitis C virus NS5A protein to block viral replication and assembly."}],"offLabel":[],"totalMarketed":0,"totalPipeline":1},"trials":{"data":[{"nct_id":"NCT00342641","title":"Association Between Hepatitis C Virus Infection and Hematologic and Thyroid Cancers","phase":"","overall_status":"COMPLETED","enrollment_count":815000,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT03944447","title":"Outcomes Mandate National Integration With Cannabis as Medicine","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":200000,"lead_sponsor_name":"OMNI Medical Services, LLC","has_results":false},{"nct_id":"NCT05071261","title":"Screening, Treatment, and Eradication of Hep C","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":112136,"lead_sponsor_name":"Liver Institute PLLC","has_results":false},{"nct_id":"NCT06596213","title":"Hepatitis Inequalities Study","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":100000,"lead_sponsor_name":"Chinese University of Hong Kong","has_results":false},{"nct_id":"NCT06155006","title":"Adult Screening for Hepatitis c and Linkage to Treatment in Hospitals in Colombia","phase":"","overall_status":"RECRUITING","enrollment_count":25669,"lead_sponsor_name":"Asociación Colombiana de Hepatología","has_results":false},{"nct_id":"NCT05906459","title":"Simplification and Test and Treat Strategies Towards Hepatitis C Eliminationplatform\" in China(STAT)","phase":"","overall_status":"UNKNOWN","enrollment_count":20000,"lead_sponsor_name":"Huashan Hospital","has_results":false},{"nct_id":"NCT07358910","title":"Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective","phase":"","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"Institut Pasteur du Cambodge","has_results":false},{"nct_id":"NCT07388979","title":"MAGIA H3S Point of Care Test Performance for HIV, HBV, HCV, and Syphilis Screening in Pregnant Women in DR Congo","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":7500,"lead_sponsor_name":"Gardiens de Vies","has_results":false},{"nct_id":"NCT03870061","title":"Evaluation of an Infant Immunization Encouragement Program in Nigeria","phase":"NA","overall_status":"COMPLETED","enrollment_count":5187,"lead_sponsor_name":"GiveWell","has_results":false},{"nct_id":"NCT04005248","title":"Prevalence of HCV in HIV-negative MSM","phase":"NA","overall_status":"UNKNOWN","enrollment_count":4000,"lead_sponsor_name":"Erasmus Medical Center","has_results":false},{"nct_id":"NCT03415334","title":"Effect of Implementation Of Outreach Behavioral Change Program for HCV Elimination","phase":"NA","overall_status":"COMPLETED","enrollment_count":3575,"lead_sponsor_name":"National Research Centre, Egypt","has_results":false},{"nct_id":"NCT02629172","title":"Drug Use-results Survey in Patients Infected With Hepatitis C Virus Genotype 1","phase":"","overall_status":"COMPLETED","enrollment_count":3043,"lead_sponsor_name":"AbbVie","has_results":false},{"nct_id":"NCT06431945","title":"Early Detection of HCV in Injection Drug Users","phase":"","overall_status":"RECRUITING","enrollment_count":3000,"lead_sponsor_name":"Institute of Health Information and Statistics of the Czech Republic","has_results":false},{"nct_id":"NCT02907996","title":"Evaluate the Safety and Effectiveness of Sovaldi in Participants With Chronic Hepatitis C Virus (HCV) Infection in Korea","phase":"","overall_status":"COMPLETED","enrollment_count":2033,"lead_sponsor_name":"Gilead Sciences","has_results":false},{"nct_id":"NCT07274345","title":"Prevalence and Risk Factors of Antiviral Resistance in Egyptian HBV Patients","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Amira Mohamed Zidan","has_results":false},{"nct_id":"NCT07038863","title":"Community Screening and Management of Hepatitis B, C and Delta in the Mongolian Population Living in France","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Hospices Civils de Lyon","has_results":false},{"nct_id":"NCT00689390","title":"Three-year Follow-up of Participants After Administration of Boceprevir or Narlaprevir for the Treatment of Chronic Hepatitis C (P05063)","phase":"PHASE2, PHASE3","overall_status":"TERMINATED","enrollment_count":1954,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT02773394","title":"Study to Describe the Actual Situation of Hepatitis C Treatment in Brazil","phase":"","overall_status":"COMPLETED","enrollment_count":1649,"lead_sponsor_name":"Janssen-Cilag Ltd.","has_results":false},{"nct_id":"NCT02292706","title":"A Registry for Participants With Cirrhosis Who Achieve a Sustained Virologic Response Following Treatment With a Sofosbuvir-Based Regimen Without Interferon for Chronic Hepatitis C Infection","phase":"","overall_status":"TERMINATED","enrollment_count":1609,"lead_sponsor_name":"Gilead Sciences","has_results":true},{"nct_id":"NCT02219490","title":"A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1596,"lead_sponsor_name":"AbbVie","has_results":true},{"nct_id":"NCT04139941","title":"Evaluation Study of HCV RDTs in Fresh Samples","phase":"","overall_status":"COMPLETED","enrollment_count":1540,"lead_sponsor_name":"Foundation for Innovative New Diagnostics, Switzerland","has_results":false},{"nct_id":"NCT05361603","title":"Acceptability of Simultaneous Screening for Viral Hepatitis B, C and HIV Among Drug Users in Non-conventional Structures","phase":"","overall_status":"RECRUITING","enrollment_count":1500,"lead_sponsor_name":"University Hospital, Limoges","has_results":false},{"nct_id":"NCT03341871","title":"Glecaprevir/Pibrentasvir Drug Use Results Survey in Patients Infected With Hepatitis C Virus Genotype 1-6","phase":"","overall_status":"COMPLETED","enrollment_count":1095,"lead_sponsor_name":"AbbVie","has_results":false},{"nct_id":"NCT02951364","title":"Harvoni in Patients With Chronic Hepatitis C Virus (HCV) Infection in Korea","phase":"","overall_status":"COMPLETED","enrollment_count":1081,"lead_sponsor_name":"Gilead Sciences","has_results":false},{"nct_id":"NCT06718530","title":"Characterization of Immune Genotypes and Antibody Profiles to Foster the discoVERY of diagnosticbioMARKERS of Liver Cancer Development","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Centro di Riferimento Oncologico - Aviano","has_results":false},{"nct_id":"NCT04387526","title":"Sofosbuvir Plus Daclatasvir With or Without Ribavirin and Chronic HCV Genotype (GT) 4","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":946,"lead_sponsor_name":"Beni-Suef University","has_results":false},{"nct_id":"NCT01598090","title":"Phase 3 Efficacy and Safety Study of Peginterferon Lambda-1a and Ribavirin With Telaprevir","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":881,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":true},{"nct_id":"NCT04038320","title":"Simplified Antiviral Treatment Strategy for Hepatitis C in Ukraine","phase":"","overall_status":"COMPLETED","enrollment_count":868,"lead_sponsor_name":"Right to Care","has_results":false},{"nct_id":"NCT05756738","title":"Acceptance and Feasibility of Hepatitis c Screening Strategies in Social Insertion Centers","phase":"NA","overall_status":"UNKNOWN","enrollment_count":854,"lead_sponsor_name":"University of La Laguna","has_results":false},{"nct_id":"NCT05657106","title":"Kentucky Outreach Service Kiosk (KyOSK): Reducing HIV, HCV, and Overdose Risk","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":752,"lead_sponsor_name":"April M Young","has_results":false},{"nct_id":"NCT02243293","title":"A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-Administration of ABT-493 and ABT-530 With and Without RBV in Subjects With Chronic Hepatitis C Virus (HCV) Genotypes 2, 3, 4, 5 or 6 Infection","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":694,"lead_sponsor_name":"AbbVie","has_results":true},{"nct_id":"NCT02167945","title":"A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":615,"lead_sponsor_name":"AbbVie","has_results":true},{"nct_id":"NCT04037046","title":"Integrating Hepatitis C Screening With Dried Blood Spot Testing Into Colorectal Cancer Screening","phase":"NA","overall_status":"COMPLETED","enrollment_count":609,"lead_sponsor_name":"University of La Laguna","has_results":false},{"nct_id":"NCT05975216","title":"Relinking Diagnosed But Untreated HCV Patients Back Into Care.","phase":"","overall_status":"COMPLETED","enrollment_count":600,"lead_sponsor_name":"Universitair Ziekenhuis Brussel","has_results":false},{"nct_id":"NCT07098481","title":"Access to Hepatitis C Treatment in Cameroon: Comparison of a Simplified Test and Treat Strategy to a Standard Strategy","phase":"PHASE4","overall_status":"NOT_YET_RECRUITING","enrollment_count":576,"lead_sponsor_name":"ANRS, Emerging Infectious Diseases","has_results":false},{"nct_id":"NCT02537379","title":"Use-Results Surveillance Study of Sovaldi® Plus Copegus® in Japanese Patients With Chronic Genotype 2 Hepatitis C Virus Infection","phase":"","overall_status":"COMPLETED","enrollment_count":552,"lead_sponsor_name":"Gilead Sciences","has_results":false},{"nct_id":"NCT00179413","title":"Study of Long-term Peg Intron vs. Colchicine in Non-responders.","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":549,"lead_sponsor_name":"Beth Israel Deaconess Medical Center","has_results":true},{"nct_id":"NCT07122219","title":"Enhancing Uptake of Needle and Syringe Programs in Canadian Federal Prisons","phase":"NA","overall_status":"RECRUITING","enrollment_count":548,"lead_sponsor_name":"McGill University Health Centre/Research Institute of the McGill University Health Centre","has_results":false},{"nct_id":"NCT03222583","title":"A Study to Evaluate the Efficacy and Safety of Glecaprevir/Pibrentasvir (ABT-493/ABT-530) in Treatment-Naive and Treatment-Experienced, Non-Cirrhotic Asian Adults With Chronic Hepatitis C Virus Genotype (GT) 1 to GT6 Infection With or Without Human Immunodeficiency Virus Co-Infection","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":546,"lead_sponsor_name":"AbbVie","has_results":true},{"nct_id":"NCT02592057","title":"Safety and Efficacy of Sofosbuvir-based Regimens in Clinical Practice for the Treatment of Chronic Hepatitis C Virus Infection in India","phase":"","overall_status":"COMPLETED","enrollment_count":532,"lead_sponsor_name":"Gilead Sciences","has_results":false},{"nct_id":"NCT05363865","title":"Digital Community to Improve Health in Rural Areas","phase":"NA","overall_status":"COMPLETED","enrollment_count":511,"lead_sponsor_name":"University of Pennsylvania","has_results":false},{"nct_id":"NCT03201718","title":"A Study of Viekira/Exviera for Korean Hepatitis C Patients According to the Standard for Re-examination of New Drugs","phase":"","overall_status":"COMPLETED","enrollment_count":505,"lead_sponsor_name":"AbbVie","has_results":false},{"nct_id":"NCT02510300","title":"A Registry for Adolescent and Pediatric Participants Who Received a Gilead Hepatitis C Virus Direct Acting Antiviral (DAA) in Gilead-Sponsored Chronic Hepatitis C Infection Trials","phase":"","overall_status":"TERMINATED","enrollment_count":461,"lead_sponsor_name":"Gilead Sciences","has_results":false},{"nct_id":"NCT02945228","title":"Drug Use-Results Survey in Participants Infected With Hepatitis C Virus Genotype 2","phase":"","overall_status":"COMPLETED","enrollment_count":449,"lead_sponsor_name":"AbbVie","has_results":false},{"nct_id":"NCT04363411","title":"Reaching Out to the UNdiagnosed People Infected With Blood Borne Viral Infections","phase":"NA","overall_status":"COMPLETED","enrollment_count":425,"lead_sponsor_name":"Hasselt University","has_results":false},{"nct_id":"NCT02105467","title":"Study of Efficacy and Safety of Grazoprevir (MK-5172)/Elbasvir (MK-8742) Combination Regimen for Treatment-Naïve Participants With Chronic Hepatitis C Virus Genotypes 1, 4, and 6 (MK-5172-060)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":421,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT02671500","title":"Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Participants With Chronic HCV","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":375,"lead_sponsor_name":"Gilead Sciences","has_results":true},{"nct_id":"NCT02581020","title":"The Durability of Response and Persistence of Resistance to AbbVie's 2 Direct-acting Antiviral Agent (2D) Therapy in Japanese Subjects","phase":"","overall_status":"COMPLETED","enrollment_count":344,"lead_sponsor_name":"AbbVie","has_results":false},{"nct_id":"NCT03089944","title":"A Study of Glecaprevir (GLE)/Pibrentasvir (PIB) in Treatment-Naive Adults With Chronic Hepatitis C Virus (HCV) Genotype 1-6 Infection and Compensated Cirrhosis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":343,"lead_sponsor_name":"AbbVie","has_results":true},{"nct_id":"NCT02639247","title":"Safety and Efficacy of SOF/VEL/VOX FDC for 12 Weeks and SOF/VEL for 12 Weeks in DAA-Experienced Adults With Chronic HCV Infection Who Have Not Received an NS5A Inhibitor","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":333,"lead_sponsor_name":"Gilead Sciences","has_results":true}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}